drugset / Trial / NCT00047190

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

NCT00047190

Phase 2 Completed 35 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of tipifarnib in treating patients who have myelofibrosis with myeloid metaplasia. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

Timeline

Start
2002-08
Primary completion
2007-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule Oral